Jemperli Cancer Drug Promises Enhanced Survival for Uterine Cancer Fighters, Reveals GSK

By -

 Jemperli, a cancer drug manufactured by GlaxoSmithKline, improved survival for patients diagnosed with a form of uterine cancer by more than one year, the British drugmaker said Saturday, the latest findings of a late-stage trial by GSK seeking to expand the use of the treatment.


Patients diagnosed with endometrial cancer showed a more than 16-month improvement in overall survival—the amount of time a patient lives after receiving a diagnosis—when using Jemperli in combination with chemotherapy, GSK said.

The findings—part of a late-stage trial by the drugmaker—also indicated treatment resulted in a 31% and 37% reduction in risk of death and risk of disease progression, respectively, when compared with just chemotherapy treatment, the drugmaker said.

Jemperli is approved by the Food and Drug Administration and the European Union to use with chemotherapy for treating some types of endometrial cancer, which forms in the womb, that are in advanced stages or have returned.

About 43.5% of women in a 108-person study found a reduction in the amount of cancer in the body or the disappearance of all signs of cancer after they used Jemperli.

Another study involving 118 women reported a “statistically significant and clinically meaningful” improvement in progression-free survival, or the amount of time a patient lives after a diagnosis in which their cancer does not worsen.

Common reactions to using Jemperli with chemotherapy include rash, diarrhea, hypothyroidism and hypertension, according to the FDA.

GSK said it would send its trial data to the FDA for regulatory approval.


66,200. That’s the average number of endometrial cancer cases diagnosed in the U.S. each year, according to Johns Hopkins Medicine. That represents about 3.4% of all new cancer cases. The average age of women diagnosed with endometrial cancer is 60, while the cancer is more uncommon under age 45, according to the American Cancer Society.

Dostarlimab—known generically as Jemperli—was developed by GSK in partnership with the biotech firm AnaptysBio in 2014, as the company expanded into cancer drug sales. The drug was approved by the FDA last year for treating advanced or recurrent cancer with carboplatin and paclitaxel, two drugs used for chemotherapy treatments. GSK has continued to research the possible benefits of using Jemperli as part of its “RUBY” trials, including possible treatment for other types of cancer.


Comments

Post a Comment

Popular posts from this blog

Characters In BBC’s Documentary On TB Joshua Unknown To Us – Synagogue Church

By -
Image
  The Synagogue Church of all Nations (SCOAN) has countered the BBC documentary on the late Temitope Babatunde Joshua, known as TB Joshua, founder of SCOAN. SCOAN described the documentary against TB Joshua as unfounded, and that the characters interviewed in the report were unknown to the church. The church, in a statement signed by its Public Affairs Director, Mr Dare Adejumo, said the statement was aimed at disabusing public minds from the report. The News Agency of Nigeria (NAN) recalls that the BBC released a highly controversial and damning documentary on the late TB Joshua on Monday, accusing him of various crimes, including rape, against some members. SCOAN said, “BBC World Services investigative unit, code-named Africa Eye, came out this week with weird and strange episodes of atrocities against the late founder of SCOAN.” It said that to investigate and publish or broadcast reports was a central kernel of journalism, but to do so outside the ethics and fundamental principles
Read more

NBA Suspends Canada’s Joshua Primo For 4 Games For Exposing Himself To Women

By -
Image
  The NBA has suspended former San Antonio Spurs guard  Joshua Primo   for four games   ... after it says it found he exposed his private parts to multiple women. The league announced the ban on Friday morning ... saying an investigation into the free agent revealed he had "engaged in inappropriate and offensive behavior." NBA officials called his actions "conduct detrimental to the league." They did, however, note that they "did not find evidence that he engaged in any sexual or other misconduct apart from these brief exposures." "Primo maintains that his conduct was not intentional," the league said. Dr. Hillary Cauthen , Primo's former therapist, was the first to  bring the allegations  against Primo to light after she claimed last fall that he exposed himself to her on nine separate occasions. Dr. Cauthen's attorney,  Tony Buzbee , alleged the Spurs were aware of Primo's actions, but didn't take action. Cauthen went on to file
Read more

Sky Sports' On-Air Mix-Up: Chelsea Players Mistakenly Introduced as Axel Disasi Instead of Noni Madueke in Carabao Cup Semifinal

By -
Image
 Sky Sports were left red-faced after an on-screen graphic mistakenly introduced Chelsea defender Axel Disasi as Noni Madueke on Tuesday night. The pair were both the scoresheet as the Blues thrashed Middlesbrough 6-1 at Stamford Bridge in the second leg of the Carabao Cup semi-final to boo their place at Wembley. But when Disasi spoke to Sky Sports after the game, an on-screen graphic introduced him as Madueke instead. Madueke is four years younger than his Chelsea teammate, plays in a different role and is English, while Disasi is French. Viewers immediately spotted the mistake and took to social media to flag up the glaring error.  Sky Sports with a huge mistake as that is Axel Disasi, not Noni Madueke,' another added, while a third described the gaffe as a 'howler'. A fourth commented: 'Sky sports calling Disasi Madueke. They’ve done it again.' Disasi scored Chelsea's third goal in the 6-1 rout, converting Raheem Sterling's cross at the far post after th
Read more